93 results about "Islet cells" patented technology

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

The invention provides a pancreatic islet organ capable of efficiently maintaining pancreatic islet beta cell identity and a preparation method and application thereof. Specifically, the invention provides the preparation method for the in-vitro pancreatic islet organ, and the preparation method comprises the following steps: carrying out induced differentiation culture on the ZnT8-knocked-out pluripotent stem cells, so as to obtain the mature pancreatic islet organ. The invention also provides a corresponding transplantation composition and application thereof. The invention discloses that ZnT8 knockout is a key factor for effectively maintaining the identity stability of beta cells in pancreatic islet organs. In addition, the pancreas islet beta cell identity maintenance agent is combined with the ZnT8-knocked-out pancreas islet organ for use, so that the identity stability of the pancreas islet organ beta cell can be obviously maintained. The invention provides a new strategy for transplantation treatment of type 2 diabetes, and has excellent clinical transformation value.

The invention provides a composition for treating diabetes as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading berberine on a milk exosome to prepare a berberine-loaded exosome, loading liraglutide on phycobiliprotein to prepare liraglutide-loaded phycobiliprotein, preparing PEG-COOH, reacting with chitosan to prepare a chitosan-polyethylene glycol graft polymer, embedding the berberine-loaded exosome and the liraglutide-loaded phycobiliprotein, and cross-linking to prepare microspheres. And centrifuging, washing and drying to obtain the composition for treating diabetes. According to the prepared composition for treating diabetes, the loading capacity of the medicine is greatly improved, the carrier also has a very good protection effect on islet cells, so that islet cell injury is repaired, normal insulin secretion of islet cells is promoted, the prepared composition can be orally taken, the medicine effect is greatly improved, the compliance of patients is improved, and the preparation method is suitable for clinical application. The bioavailability is high, and safety and non-toxicity are realized.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

While there have been reports of cultivating islet-like insulin-producing cells by inducing differentiation of ES / iPS cells, the technology for cultivating high-functioning, large-scale insulin-positive islet cells is not yet mature, and there are concerns about rejection and unexpected immune responses. The present invention provides islet-like cells into which the Mycl gene has been introduced, as well as methods for inducing the proliferation of islet-like cells and their differentiation into insulin-producing cells through transient expression of the Mycl gene.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

The utility model relates to the technical field of preserving fluid bottles, in particular to a preserving fluid bottle for islet cells, which comprises a bottle body, a bottle cap is screwed at the top end of the bottle body, a plug is integrally formed on the surface of the bottle cap, a rubber cover is fixed inside the plug, an elastic band ring is fixed at one end of the rubber cover, and after the rubber cover is turned outwards and sleeved on the outer side of the bottle body, the elastic band ring is fixed at the other end of the rubber cover. The elastic band ring is positioned below the bottle body; the preserving fluid bottle for the islet cells has the advantages that due to the design of the rubber cover, the rubber cover can be contained between the chock plug and the baffle when the preserving fluid bottle is not used, the rubber cover can be turned outwards to be arranged on the outer side of the bottle body in a sleeving mode, the shading effect is achieved, and the islet cells are protected against light damage. After the rubber cover is turned outwards and arranged on the outer side of the bottle body in a sleeving mode, the anti-collision capacity of the bottle body can be improved, and the bottle body is prevented from being damaged due to collision in the transportation or storage process. Due to the design of the elastic band ring, the rubber cover can be firmly fixed to the bottle body and is not prone to falling off, and meanwhile a user can conveniently take down or sleeve the rubber cover at any time according to needs.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The application discloses a temperature-sensitive hydrogel with a diabetes treatment effect, a kit, a use method and application thereof, and belongs to the technical field of diabetes treatment drugs. The temperature-sensitive hydrogel is formed by mixing a human umbilical vein endothelial cell suspension, a mixed solution with a final concentration of 15-20% of P407 and a final concentration of 0.6-0.8% of sodium hyaluronate, a final concentration of 50 ng / mL of vascular endothelial growth factor, a final concentration of 10 ng / mL of basic fibroblast growth factor, a final concentration of 0.5-2% of lidocaine hydrochloride, a final concentration of 100-200 mg / mL of tumor necrosis factor alpha monoclonal antibody and a final concentration of 2-5% of islet cell-alginic acid gel fiber segments with a length of less than 1 mm. The temperature-sensitive hydrogel is safe, non-toxic, low in immunogenicity, low in cost and good in treatment effect. The reagent is combined with sterile consumables to form a kit, and the kit is convenient to use and can be better applied to the treatment of diabetes.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The invention provides application of circRNA 3254 in preparation of a preparation or a medicine for preventing early apoptosis of transplanted islet cells, belongs to the technical field of islet transplantation, and aims to solve the important problems of relieving the early transplanted islet apoptosis, improving the transplanted islet function and prolonging the time of completely separating from insulin after transplantation in the current islet transplantation field. A circRNA sequencing result finds that circRNA participates in a process of improving the curative effect of transplanted pancreas islet by bone marrow mesenchymal stem cells (BMSCs) for the first time, and circRNA 3254 which is not reported in literatures is screened as a research target. The specific regulation effect of circRNA 3254 on the apoptosis condition of the early transplanted pancreas islet is verified in in-vivo and in-vitro models for the first time, and a mechanism network for improving the survival rate of the transplanted pancreas islet by the BMSCs is further improved. The specific regulation effect of circRNA 3254 on the apoptosis condition of the early transplanted pancreas islet is verified in in-vivo and in-vitro models for the first time, and a mechanism network for improving the survival rate of the transplanted pancreas islet by the BMSCs is further improved.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

Disclosed herein are compositions and methods useful for manufacturing SC-β cell, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

An encapsulation device system for therapeutic applications such as but not limited to regulating blood glucose. The system may comprise an encapsulation device with a first oxygen sensor integrated inside the device and a second oxygen sensor disposed on an outer surface of the device, wherein the sensors allow for real-time measurements (such as oxygen levels) related to cells (e.g., islet cells, stem cell derived beta cells, etc.) housed in the encapsulation device. The system may also feature an exogenous oxygen delivery system operatively connected to the encapsulation device via a channel, wherein the exogenous oxygen delivery system is adapted to deliver oxygen to the encapsulation device.

The invention discloses application of tacrolimus in preparation of a medicine for treating type 2 diabetes and complications thereof, and belongs to the field of biological medicine. Animal experiments prove that Tacrolimus (TM) can effectively improve type 2 diabetes mellitus and obesity-related abnormal glycolipid metabolism. In addition, the TM can also relieve liver injury caused by diabetes and obesity and improve liver fatty degeneration and abnormal lipid metabolism. What's more important is that toxicity of TM to pancreatic beta cells is not observed in long-term multi-model experiments (including diabetes, obesity and elderly mice). The invention provides an important basis for developing novel diabetes treatment drugs, lays a foundation for expanding new indications of tacrolimus, and has potential clinical transformation value.

The utility model discloses an islet cell storage device, and relates to the technical field of storage devices. The test tube storage device comprises a cold closet, a top cover is pressed on the top of the cold closet, an insertion opening is formed in the bottom face of the top cover, a storage test tube is movably inserted into the inner wall of the insertion opening, and a clamping assembly used for limiting the storage test tube is arranged on the surface of the cold closet. A lifting control assembly used for controlling the top cover to move up and down is arranged on the front face of the refrigerating box, the refrigerating box is filled with liquid nitrogen, the clamping assembly comprises a first lead screw, the first lead screw is in threaded connection with the top cover, the rear end of the first lead screw is fixedly connected with a first rotary knob, and the front end of the first lead screw is rotationally connected with a clamping block. The islet cell storage and transportation device has the advantages that islet cells can be conveniently stored and transported during use, test tubes filled with islet cell samples can be quickly taken out of the device, the test tubes can be taken more conveniently and safely, and the islet cell storage and transportation device is good in practicability.

The invention relates to the field of biological medicines, in particular to application of a hepatocyte nuclear factor 1 alpha (HNF1 alpha) in promoting beta cell regeneration and preventing and treating diabetes. Specifically, by regulating and controlling the expression of an HNF1alpha coding gene and the activity of HNF1alpha, pancreas islet alpha cells can be promoted to be transdifferentiated into beta cells to achieve beta cell regeneration, the functions of pancreas islet beta cells are reserved, the occurrence of diabetes mellitus is delayed, and a new medical approach is provided for prevention and treatment of diabetes mellitus.

The utility model discloses a circulating water cooling tank for cell preservation, and relates to the field of experimental instruments. According to the scheme, the water cooling tank comprises a water cooling tank body, a cooling machine and a cooling cup, a flow baffle is fixedly installed in the water cooling tank body, a first sealing gasket is assembled above the water cooling tank body, a tank cover is arranged above the first sealing gasket, handles are assembled on the two sides of the tank cover, and a special-shaped groove is formed in the surface of the tank cover; a water inlet pipe and a water outlet pipe are arranged on the two sides of the cooler, a micro pump is arranged at the top end of the cooler, a center console is arranged on the front face of the cooler, a second sealing gasket and a third sealing gasket are arranged at the two ends of the cooling cup, and a check block is assembled on the outer curved surface of the cooling cup. The micro pump is utilized to enable the water-cooling liquid in the water-cooling tank body to form dynamic circulation, so that all islet cells placed in the water-cooling tank body can be cooled, meanwhile, the cooling machine can be used for adjusting the temperature of the water-cooling liquid in the water-cooling tank body, and storage environment pollution caused by replacement of the water-cooling liquid is avoided.

The invention relates to the technical field of gene engineering, in particular to a construction method and application of a mouse model with an islet beta cell specificity knockout Osge gene. The construction method comprises the following steps: 1) according to the structure of an Osge gene, determining that a knockout region is a second exon region and a third exon region, the CDS sequence of an Osge gene transcript is as shown in SEQ ID NO.1, designing a gene segment of which two ends are connected with flox sites and which comprises a knockout region sequence, and inserting the segment into a plasmid; 2) designing sgRNA according to the upstream sequence and the downstream sequence of the knockout region; and 3) uniformly mixing the sgRNA, Cas9 enzyme and plasmid, injecting the mixture into cytoplasm of the mouse fertilized eggs, and constructing and editing the mouse fertilized eggs to produce F0-generation mice. The research finds that the Osge knockout mouse can be used for researching diabetes, and the Osge gene can play a role in treating the diabetic mouse.

Methods and systems for measuring viability and function of islet cells or stem cell-derived beta cells in an implantable device featuring setting the temperature of the cells in the implantable device to a low temperature to reduce metabolic levels of the cells and reduce oxygen requirements of the cells, and measuring oxygen consumption rates. An oxygen sensor at the inlet of the implantable device and an oxygen sensor at the outlet of the implantable device are used to calculate oxygen consumption rates of the cells, which in turn are indicative of viability. The reduction in temperature can also be used for loading cells into the implantable devices to help reduce ischemic and / or physical injury. The present invention may be used with other cell types, e.g. hepatocytes, heart cells, muscle cells, etc.

The application discloses a frozen embedding block of islet cell-like cell clusters meeting spatiotemporal omics continuous section analysis, a method and application thereof, and belongs to the field of frozen embedding block preparation. In order to solve the problem of RNA / DNA integrity and visualization of islet cell clusters, the method comprises the following steps: adding a buffer solution containing bromophenol blue drop by drop to the aggregated cell clusters on the inner surface of the bottom of a silk cloth to dye the cell clusters; keeping the selected area of the silk cloth in contact with the frozen embedding reagent surface of the lower half groove in the loading groove of a first mold, placing the first mold on dry ice, and completely freezing the frozen embedding reagent of the lower half groove and the cell clusters on the surface thereof; placing the first mold with the upper half groove frozen embedding reagent added in the loading groove on dry ice, completely freezing the frozen embedding reagent of the upper half groove and the cell clusters on the surface thereof, and making the frozen embedding reagent of the upper half groove and the frozen embedding reagent of the lower half groove be integrated into the frozen embedding block, and taking out the frozen embedding block, wherein the cell clusters are distributed at the middle position on the height of the frozen embedding reagent block.

The invention discloses an application of WBSCR16 protein as a target spot in preparation of a medicine for treating diabetes, and provides an application in research and development of related medicines. By constructing a mouse model of Wbscr16 with pancreatic beta cells specifically knocked out, the action mechanism of WBSCR16 in diabetes mellitus attack is deeply researched, and it is found that WBSCR16 participates in regulating the mitochondrial function of the pancreatic beta cells, and then insulin secretion is affected. On the basis, the invention provides a reagent for regulating the expression of the WBSCR16 protein for treating diabetes mellitus. Meanwhile, a construction method of the Wbscr16 pancreatic beta cell specific knockout mouse model is described in detail, and an important tool is provided for related research. Meanwhile, candidate drugs capable of acting on a WBSCR16 target spot are screened out through drug prediction, and a new strategy and a potential intervention direction are provided for treatment of diabetes mellitus.

The invention discloses a pharmaceutical composition for reducing blood sugar and application thereof, and belongs to the technical field of preparation of drugs for reducing blood sugar. The pharmaceutical composition is prepared from the following components in parts by weight: 5 to 7 parts of empagliflozin, 30 to 40 parts of cortex cinnamomi extract, 500 to 700 parts of metformin, 60 to 80 parts of microcrystalline cellulose, 10 to 15 parts of polyvinylpolypyrrolidone, 100 to 120 parts of HPMC K100M, 50 to 60 parts of ethyl cellulose, 40 to 50 parts of Eudragit FS30D, 40 to 50 parts of soybean phospholipid and 10 to 20 parts of poloxamer 188. The composition is applied to preparation of sustained-release tablets for reducing blood sugar, and can reduce loss of islet cells and protect kidney functions and gastric mucosa.

The invention relates to the technical field of cell engineering, in particular to a method for inducing Muse cells to differentiate into pancreatic beta cell spheres through balling / adherent alternate culture and application. Experimental results in the invention show that the Muse cells subjected to static balling culture are obvious in apoptosis due to hypoxia in spheres, and almost all the cells are apoptotic after being cultured for 23 days; the Muse cells subjected to direct adherent induction culture are high in proliferation capacity, and the differentiation efficiency is 37.7%; a balling and adherent alternate culture induction mode is adopted, so that stable passage can be realized, and the differentiation efficiency is 62.4%; the alternative culture induction method effectively solves the problems of proliferation and differentiation efficiency, and realizes stable passage and induced differentiation of the pancreatic beta cells.

The present application provides a traditional Chinese medicine composition with blood sugar lowering efficacy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines; the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: birch juice 140-200 parts, jujube fruit 20-40 parts, rehmannia 20-40 parts, adenosma 18-26 parts, periploca 18-26 parts, ophiopogon 18-26 parts, bamboo shavings 12-19 parts, leech 12-19 parts, psyllium 12-19 parts, dogwood 10-14 parts, gordon euryale seed 10-14 parts. In the traditional Chinese medicine composition, the blood sugar lowering effect is mainly achieved by repairing the function of islet beta cells, promoting the regeneration of islet beta cells, improving sugar metabolism, increasing the sensitivity of insulin or improving insulin resistance, so that the overall prescription achieves the effects of invigorating the spleen and lung, nourishing yin and reducing fire, benefiting the stomach and producing saliva, astringing the spleen essence, promoting transportation and transformation, tonifying the kidney and strengthening the body, and relieving polydipsia and restlessness.

Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.

The invention provides a pharmaceutical composition helpful for reducing blood glucose as well as a preparation and application thereof, and relates to the field of medicines. The pharmaceutical composition helpful for reducing blood glucose comprises the following raw materials in parts by weight: 15-20 parts of pomegranate, 8-13 parts of turmeric, 1-2 parts of bear gall, 1-2 parts of schisandra chinensis, 10-15 parts of dendrobe, 5-10 parts of folium eriobotryae, 8-12 parts of radix puerariae, 5-10 parts of dandelion, 8-15 parts of herba epimedii, 8-12 parts of polygonum cuspidatum, 5-8 parts of gynostemma pentaphyllum, 4-8 parts of inula flower and 3-5 parts of cortex lycii radicis. The pharmaceutical composition disclosed by the invention effectively inhibits sugar absorption of intestinal tracts, enhances insulin sensitivity, improves insulin resistance, promotes activity of glucose transporter protein, regulates glycolipid metabolism balance, inhibits liver glycogen decomposition to reduce liver glucose output and reduces interference of inflammatory factors on insulin signal channels through a multi-channel synergistic effect; therefore, the whole metabolic regulation is optimized, the blood sugar level is remarkably reduced, the number of pancreatic beta cells is increased, and the compound can be applied to preparation of drugs for treating diabetes.

The invention discloses a mulberry leaf fermentation composition helpful for reversing insulin resistance and a preparation method thereof, relates to the technical field of mulberry leaf fermentation treatment, and solves the problem that in the prior art, a technology for preparing auxiliary materials for assisting diabetes treatment from mulberry leaves and related products do not exist. The mulberry leaf fermentation composition is prepared from a mulberry leaf extract, a highland barley extract, a bitter gourd extract, hawthorn powder, yam flour, lemon powder, fructo-oligosaccharide, water-soluble dietary fibers, resistant dextrin and a fermentation microbial preparation, wherein the highland barley extract is prepared by mixing a highland barley flavone extract and a highland barley polysaccharide extract according to a mass ratio of (4-6): 1. Through multi-channel combination of'inhibiting sugar absorption, enhancing insulin signals, protecting islet cells and improving metabolism ', insulin signal channels can be effectively improved, inflammatory oxidative stress can be relieved, glucose and lipid metabolism disorder can be regulated, and insulin resistance can be reversed.